Sign up
Pharma Capital
Market: ASX
52-week High/Low: A$0.37 / A$0.23
Sector: Pharma & Biotech
Market Cap: A$105.51M

Pharmaxis Ltd (ASX:PXS) is a specialty pharmaceutical company focused on the development of new products for the diagnosis and treatment of chronic respiratory and immune disorders.

Pharmaxis Ltd

Interactive graph

col 3
col 4
col 5
col 6

Pharmaxis Ltd Snapshot

Pharmaxis is an Australian pharmaceutical research company with a portfolio including two respiratory products approved in various world markets and a research pipeline focused on areas of high unmet clinical need in inflammatory and fibrotic diseases.

Established in 1998 and listed on the Australian Securities Exchange in 2003 (symbol PXS) the Company’s head office, manufacturing and research facilities are located in Sydney, Australia.

(click here for more information)


Bronchitol is approved for the treatment of certain patients with cystic fibrosis to help them clear mucus from their lungs.

Bronchitol is dry powder mannitol which is inhaled twice daily using a small handheld device. Bronchitol works by rehydrating the airway/lung surface and promoting a productive cough. Clinical trials have shown that Bronchitol helps to increase mucus clearance, and improve the lung function and the quality of life of people living with cystic fibrosis.

(click here for more information)


Pharmaxis' first commercial product, Aridol is an innovative lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. Patients inhale increasing doses of Aridol via a simple hand-held device.

(click here for more information)

Last updated 7th June 2016.

Malcolm J McComas
BEc LLB - Independent Chairman

Malcolm has been a member of the Board of Directors since July 2003 and Chairman of the Board since 2012. He is a company director, former investment banker and commercial lawyer. Malcolm is the principal of McComas Capital and was previously a director of investment banking and funds management group Grant Samuel.

Malcolm is a former Managing Director of investment banking at County NatWest and its successor organisation Salomon Smith Barney (now Citigroup). He has held various executive roles with Morgan Grenfell (now Deutsche Bank) in Melbourne, Sydney and London.

Malcolm has worked with many high growth companies across various industry sectors and has experience in equity and debt finance, acquisitions and divestments and privatisations. He has led more than 50 initial public offerings and significant secondary offerings for companies, institutions and governments. Malcolm is Chairman of Fitzroy River Corporation Limited, a director of Saunders International Limited and the Australasian Leukaemia and Lymphoma Group and a senior advisor to CW Downer & Co.  He was the former President of Finsia (the Financial Services Institute of Australia) and previously a director of Consolidated Minerals Limited, Ocean Capital Limited and BC Iron Limited. 

Malcolm is chairman of the Pharmaxis Remuneration and Nomination Committee and a member of the Audit Committee.

Gary J Phillips
B Pharm MBA - Chief Executive Officer

Gary joined the Company in 2003 and was appointed Chief Executive Officer and became a member of the Board of Directors in March 2013. He previously held the positions of Commercial Director and Chief Operating Officer. Gary has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.

From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (merged to form Novartis in 1996) where he led the successful launch of a portfolio of new products.  After a period of 3 years as an area manager for Novartis responsible for 9 countries in Asia Pacific in 2001 he joined Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division, successfully launching leading oncology and ophthalmology products. Gary holds a BPharm in Pharmacy with honors from Nottingham University in the UK and an MBA from Henley Management College.

William L Delaat
AM BSc - Non-Executive Director

Will has been a member of the Board of Directors since June 2008. He has more than 35 years’ experience in the global pharmaceutical industry, most recently as the Managing Director of the Australian subsidiary of Merck & Co, a position he held from 1997 until his retirement in 2008.

During his career Will has held executive positions in both Europe and Australia for Merck and AstraZeneca. He has a broad depth of experienced in pharmaceutical sales and marketing and has been responsible for numerous international product launches.

Will was Chairman of the pharmaceutical peak body Medicines Australia, and the Pharmaceuticals Industry Council from 2008-2012. He is also Chairman of EnGeneIC Ltd, an unlisted Australian biotech company, and a director of the George Institute for Global Health Board.

Will holds a Bachelor of Science, Physiology & Chemistry, from the University of London.

Will is Chair of the Pharmaxis Audit Committee and a member of the Remuneration and Nomination Committee.

Simon HW Buckingham

BVSc (Hons) PhD - Non-Executive Director

Simon has been a member of the Board of Directors since July 2012. He has over 25 years’ experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas. Now based in Sydney, Simon is currently a senior global advisor to Actelion, one of the world’s leading biopharmaceutical companies, and is a director of Actelion Australia. He was President, Global Corporate and Business Development at Actelion from 2005-2011, a position which spanned licensing, M&A, alliance management and corporate strategic planning. Simon served as President, North America and Asia-Pacific at Actelion from 2000-2005, with responsibility for all commercial operations in the region. He was the founding President of Actelion Pharmaceuticals US. From 1998-2000 he worked in sales and marketing for Parke-Davis (now part of Pfizer) in the US and prior to that served in roles in sales, marketing and development at Roche, both in Switzerland and Australia, for 9 years.

Simon is currently a non-executive director of European based Vaxxilon and also of the Can Too Foundation, a non-profit organisation raising funds for cancer research. He holds a Bachelor of Veterinary Science degree from the University of Sydney, a PhD from the University of Melbourne, a Graduate Management Qualification from the AGSM, University of NSW and is a Graduate of the Australian Institute of Company Directors. Simon is a member of the Pharmaxis Audit Committee and the Remuneration & Nomination Committee.

David M McGarvey
BA CA CPA - Company Secretary and Chief Financial Officer

David has been Chief Financial Officer and Company Secretary since December 2002. He is a seasoned CFO with thirty years’ experience building and funding Australian based companies from inception to globally successful enterprises.

From 1998 to 2002 David served as Chief Financial Officer of the Filtration and Separations Division of US Filter. From 1985 to 1997 he served as Chief Financial Officer of Memtec Limited. While at Memtec and US Filter, David oversaw the US listing of the company on the Nasdaq Global Market and the New York Stock Exchange and managed numerous international merger and acquisition transactions. From 1975 to 1985, he held various positions at PriceWaterhouseCoopers.

David holds a BA in Accounting from Macquarie University and was admitted to the Chartered Accountants Australia and New Zealand in 1981 and to the membership of CPA Australia in 1993.

Last updated 7th June 2016.

The top 20 Shareholders in Pharmaxis Ltd on 31 March 2015 are:

NameNumber% Total
1. Citicorp Nominees Pty Limited 68,191,170 21.90%
2. National Nominees Limited 24,714,344 7.90%
3. HSBC Custody Nomiees (Australia) Limited 15,224,967 4.90%
4. JP Morgan Nominees Australia Limited 13,760,790 4.40%
5. Haydos Corporation Pty Ltd 2,850,000 0.90%
6. George Engineering Pty Ltd (PG Super Fund) 2,500,000 0.80%
7. Pakasoluto Pty Limited (Barkl Family Super Fund A/C) 2,491,249 0.80%
8. Mr Sunder Raj Eswara + Mrs Kalavathy Sunder Raj 2,160,000 0.70%
9. Simgon Pty Ltd 1,750,000 0.60%
10. David & Merryl Super Pty Ltd (David & Merryl S/F A/C) 1,710,667 0.60%
11. Mr David Robert Newnham + Ms Merryl Barbara Kate (DRN Superfund No 1 A/C) 1,481,979 0.50%
12. Alpha Matilda Trading Pty Ltd (Alpha Matilda Superfund A/C 1,420,839 0.50%
13. Mr David Robert Newnham + Ms Merryl Barbara Kate (DRN Superfund No 2 A/C) 1,405,056 0.50%
14. Mr Brian Tully & Mrs Margaret Tully (Superannuation Fund A/C) 1,265,000 0.40%
15. Dr Mark Edwin Badcock 1,245,697 0.40%
16. Springwood Solar Pty Ltd 1,220,000 0.40%
17. Mr Marco Andrea Negro 1,200,000 0.40%
18. Killcare Holdings Pty Ltd 1,188,174 0.40%
19. Capital Regional et Cooperatif Desjardins 1,053,867 0.30%
20. Brecus Pty Ltd (Brecus Super Fund A/C) 1,000,000 0.30%


Last updated 18th June 2015.

Investors, corporate and financial

David McGarvery
Chief Financial Officer & Company Secretary
P | +61 2 9454 7200
E | [email protected]

Felicity Moffatt
Media Contacts
M| +61 (0) 418 677 701
E |  [email protected]

Lisa Nolan
Partner and collaboration contacts
P |  +1 (302) 575 9241
M | +1 (302) 345 5525
E | [email protected]

Clinical trials, product information and medical information
P | Australia Head Office Phone: +61 2 9454 7200
E | [email protected]

Adverse events
E | [email protected]
F | + 61 2 9454 7255

Customer  Information
E | [email protected]

Head Office - Australia
Pharmaxis Ltd
20 Rodborough Road
Frenchs Forest NSW 2086

Mailing Address:
Locked Bag 5015
Frenchs Forest NSW 2086

P | +61 2 9454 7200
F | +61 2 9451 3622
E | [email protected]

UK Mailing Address
Pharmaxis Pharmaceutical Limited
25 Moorgate, London, EC2R 6AY, England

Malcolm McComas - Chairman
Gary Phillips - Chief Executive Officer
Simon Buckingham – Non Executive Director
Will Delaat – Non Executive Director
Company Secretary and Chief Financial Officer

David McGarvey
E | [email protected]

Investor relations enquiries
David McGarvey
E | [email protected]

Media enquiries
Felicity Moffatt
E| [email protected]

Partnership and collaboration enquiries
Lisa Nolan
E | [email protected]

Registered office
20 Rodborough Road
Frenchs Forest NSW 2086

Telephone: +61 2 9454 7200
Fax: +61 2 9451 3622
Email: [email protected]

Securities exchange listings
Pharmaxis shares are listed on the Australian Stock Exchange (Code: PXS)

Pharmaxis American Depositary Receipts are traded on the US over-the-counter market (Code: PXSLY)

Legal advisors

PFM Legal Pty Ltd
Level 7, 257 Clarence Street
Sydney NSW 2000

Darling Park Tower 2
201 Sussex Street
Sydney NSW 2000


Westpac Banking Corporation

Share registry
Computershare Investor Services Pty Ltd
Level 3, 60 Carrington Street
Sydney NSW 2000

Telephone: 1300 855 080
                  +61 (03) 9415 4000

American depositary receipts
BNY Mellon Shareowner Services
P.O. Box 30170

College Station, TX 77842-3170

Telephone: 1-888-BNY-ADRS (1-888-269-2377)

(toll free number for domestic callers)

International: +1 201 680 6825

Last updated 8th June 2016.

View full PXS profile View Profile
View All

Market Reports Including PXS


Executive video interviews


© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.